JP2022534433A5 - - Google Patents

Info

Publication number
JP2022534433A5
JP2022534433A5 JP2021570997A JP2021570997A JP2022534433A5 JP 2022534433 A5 JP2022534433 A5 JP 2022534433A5 JP 2021570997 A JP2021570997 A JP 2021570997A JP 2021570997 A JP2021570997 A JP 2021570997A JP 2022534433 A5 JP2022534433 A5 JP 2022534433A5
Authority
JP
Japan
Prior art keywords
antigen
gal9
immune cells
activated immune
control agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534433A (ja
JP7797203B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050546 external-priority patent/WO2020237320A1/en
Publication of JP2022534433A publication Critical patent/JP2022534433A/ja
Publication of JP2022534433A5 publication Critical patent/JP2022534433A5/ja
Priority to JP2025107319A priority Critical patent/JP2025146842A/ja
Application granted granted Critical
Publication of JP7797203B2 publication Critical patent/JP7797203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570997A 2019-05-31 2020-05-29 抗ｇａｌ９免疫阻害性結合分子 Active JP7797203B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107319A JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855590P 2019-05-31 2019-05-31
US62/855,590 2019-05-31
US201962900105P 2019-09-13 2019-09-13
US62/900,105 2019-09-13
PCT/AU2020/050546 WO2020237320A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107319A Division JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Publications (3)

Publication Number Publication Date
JP2022534433A JP2022534433A (ja) 2022-07-29
JP2022534433A5 true JP2022534433A5 (https=) 2023-06-07
JP7797203B2 JP7797203B2 (ja) 2026-01-13

Family

ID=73552467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570997A Active JP7797203B2 (ja) 2019-05-31 2020-05-29 抗ｇａｌ９免疫阻害性結合分子
JP2025107319A Withdrawn JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107319A Withdrawn JP2025146842A (ja) 2019-05-31 2025-06-25 抗ｇａｌ９免疫阻害性結合分子

Country Status (10)

Country Link
US (1) US20220227873A1 (https=)
EP (1) EP3976102A4 (https=)
JP (2) JP7797203B2 (https=)
KR (1) KR20220030934A (https=)
CN (1) CN114025797A (https=)
AU (1) AU2020285369A1 (https=)
CA (1) CA3141640A1 (https=)
IL (1) IL288561A (https=)
SG (1) SG11202113132YA (https=)
WO (1) WO2020237320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220235135A1 (en) * 2019-05-31 2022-07-28 The Council Of The Queensland Institute Of Medical Research Activating anti-gal9 binding molecules
CR20240489A (es) * 2022-05-13 2025-01-07 Exelixis Inc Agentes aglutinantes 5t4 y usos de los mismos
PE20252168A1 (es) * 2023-01-27 2025-09-04 Exelixis Inc Agentes de union nkg2a y usos de estos
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511085A1 (en) * 1993-03-05 1994-09-15 Universite Catholique De Louvain Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003033709A2 (en) * 2001-10-17 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
WO2016008005A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2022534433A5 (https=)
US20220135676A1 (en) Multispecific antigen binding proteins
CA3211163A1 (en) Trispecific antibody targeting bcma, gprc5d, and cd3
JP2022514693A5 (https=)
CN110536903A (zh) 抗ox40抗体及其用途
JP2019201643A5 (https=)
WO2015197582A1 (en) Monomeric multispecific antigen binding proteins
WO2018108106A1 (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
RU2018135247A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
JP2021524478A5 (https=)
JP2020515247A5 (https=)
JP2018501297A (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
WO2009140348A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
AU2015279316A1 (en) Multispecific NKp46 binding proteins
RU2012122203A (ru) Композиции и способы для лечения восполительных нарушений
JP2015130883A (ja) Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
RU2018126297A (ru) Антитела, нацеленные на cd32b, и способы их применения
JP2012501670A5 (https=)
US20230114801A1 (en) MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
JP2013509158A5 (https=)
JP2020518248A5 (https=)
EP3713959A1 (en) Multispecific antigen binding proteins
GB2578037A (en) Therapeutic anti-CD40 ligand antibodies
JP2021520201A5 (https=)
WO2023060277A1 (en) Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof